Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update

Fibrinolysis and Proteolysis

Volumn 9, Issue 5, 1995, Pages 263-276

  van Meijer, M ^a   Pannekoek, H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

CHEMICAL STRUCTURE; FIBRINOLYSIS; GENE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0028786263     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(95)80015-8     Document Type: Review

References (157)

1. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation
2. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on haemostasis, thrombosis, and thrombolysis
3. Adenovirus-mediated gene transfer of recombinant t-PA restores thrombolysis in t-PA deficient mice
4. On the regulation and control of fibrinolysis
5. Importance of intramolecular interactions in the control of the fibrin affinity and activation of human plasminogen
6. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
7. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2
8. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis
9. 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity
10. The course and prerequisites of Lys-plasminogen formation during fibrinolysis
11. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
12. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system
13. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor
14. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1
15. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding
16. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
17. Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis
18. Human plasma proteinase inhibitors
19. Serpins: the superfamily of plasma serine proteinase inhibitors
20. Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins
21. Antithrombin-III-Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity
22. Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene
23. Serine proteases: structure and mechanism of catalysis
24. The covalent nature of the human antithrombin III-thrombin bond
25. Properties of antithrombin-thrombin complex formed in the presence and in the absence of heparin
26. Evidence for a tetrahedral intermediate complex during serpin-proteinase interactions
27. Structural transition of α-1-antitrypsin by a peptide sequentially similar to beta-strand s4A
28. Substrate properties of C1 inhibitor Ma (alanine 434—glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status
29. Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor
30. Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function
31. Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor
32. Crystal structure of ovalbumin as a model for the reactive centre of serpins
33. Plasminogen activator inhibitor type-1 reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
34. The mechanism of the reaction between human plasminogen activator inhibitor 1 and tissue plasminogen activator
35. Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
36. Crystallization, activity assay and preliminary X-ray diffraction analysis of the uncleaved form of the serpin antichymotrypsin
37. Biological implications of a 3 Å structure of dimeric antithrombin
38. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions
39. Structural basis of latency in plasminogen activator inhibitor-1
40. Kinetic characterization of the substrate reaction between a complex of antithrombin with a synthetic reactive-bond loop tetradecapeptide and four target proteinases of the inhibitor
41. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor
42. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
43. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family
44. cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1)
45. Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1
46. Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns
47. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family
48. Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences
49. Plasminogen activator inhibitor type 1 gene is located at region q21.3–q22 of chromosome 7 and genetically linked with cystic fibrosis
50. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells
51. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties
52. Mutational and immunochemical analysis of plasminogen activator inhibitor 1
53. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli
54. Processing of type 1 plasminogen activator inhibitor (PAI-1) into the regulated secretory pathway
55. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets
56. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood
57. An inhibitor of plasminogen activator in rabbit endothelial cells
58. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells
59. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue
60. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
61. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
62. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel wall
63. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins
64. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. [Review]
65. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288
66. Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization
67. Platelet metabolism and activation
68. The behaviour of plasminogen activator inhibitor released from activated platelets
69. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells
70. Stability of plasminogen activator inhibitor 1 (PAI-1)
71. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin
72. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability
73. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
74. Molecular evolution of plasminogen activator inhibitor-1 functional stability
75. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor
76. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma
77. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma Identification as a multimeric form of S protein (vitronectin)
78. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells
79. Stability of plasminogen activator inhibitor 1 (PAI-1)
80. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin
81. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor
82. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
83. Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1
84. Structure and biological role of vitronectin [Review]
85. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin
86. Complex formation between plasminogen activator inhibitor 1 and vitronectin in purified systems and in plasma
87. Localization of vitronectin binding domain in plasminogen activator inhibitor-1
88. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1)
89. Localization of a vitronectin binding region of plasminogen activator inhibitor-1
90. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants
91. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation
92. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. Use in mapping the PAI-1 binding site
93. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin
94. Identification of a PAI-1 binding site in vitronectin
95. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor
96. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin
97. The PAI-1/vitronectin interaction: two cats in a bag?
98. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties
99. Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin
100. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix
101. Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin
102. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site
103. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1
104. Antithrombin and related inhibitors of coagulation proteinases
105. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin
106. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. Evidence for a template model for the mechanism of action of heparin
107. A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin
108. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA
109. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution
110. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator mediated fibrinolysis
111. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance
112. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin
113. The specific roles of the finger and the kringle-2 domain of tissue-type plasminogen activator during in vitro fibrinolysis
114. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus
115. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator
116. Attenuation of thrombolysis by plasminogen acivator inhibitor type-1 in platelets
117. Serpin-resistant mutants of human tissue-type plasminogen activator
118. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1
119. Restoration of serine protease-inhibitor interaction by protein engineering
120. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center
121. Combinatorial mutagenesis of the reactive site region in plasminogen activator inhibitor
122. Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases
123. Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1
124. Functional display of human plasminogen-activator inhibitor 1 (PAI-1) on phages: novel perspectives for structure-function analysis by error-prone DNA synthesis
125. Phage display to study the interaction of PAI-1 with the VR-1 region of t-PA
126. Conformational states of vitronectin: preferential expression of an antigenic epitope when vitronectin is covalently and noncovalently complexed with thrombin-antithrombin III or treated with urea
127. Conformational lability of vitronectin: induction of an antigenic change by a-thrombin-serpin complexes and by proteolytically modified thrombin
128. Ternary vitronectin-thrombin-antithrombin III complexes in human plasma. Detection and mode of association
129. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma Identification as a multimeric form of S protein (vitronectin)
130. Thrombin and the thrombin-thrombomodulin complex interaction with plasminogen activator inhibitor type-1
131. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate
132. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator
133. Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin
134. Serpins are suicide substrates: implications for the regulation of proteolytic pathways
135. Suicide substrates, mechanism-based enzyme inactivators: recent developments. [Review]
136. Kinetics of suicide substrates. Practical procedures for determining parameters
137. The characterization of enzyme inhibition
138. Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of α-thrombin
139. Antithrombin and its deficiency states. [Review]
140. Effects of mutations in the hinge region of serpins
141. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop
142. Substrate behaviour of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the active site loop
143. Monoclonal antibodies switching active plasminogen activator inhibitor-1 to substrate
144. Platelets and thrombolytic therapy
145. In vitro thrombotic coagulation of the blood
146. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop
147. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis
148. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms
149. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators
150. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of α2-antiplasmin to fibrin
151. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism
152. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo
153. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis [see comments]
154. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1 neutralizing monoclonal antibody
155. Suicide substrates for flavoprotein enzymes
156. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)